The β-blocker carvedilol had no impact on left ventricular ejection fraction (LVEF) in women with breast cancer undergoing chemotherapy, found a study in the Journal of the American College of Cardiology.
The study enrolled 200 patients with breast cancer who had normal LVEF and were scheduled to receive anthracycline (ANT) chemotherapy. Patients were randomly assigned to receive either carvedilol (median daily dose of 18.4 mg/d) or placebo when starting ANT chemotherapy.
Slomski A. Carvedilol During Chemotherapy. JAMA. 2018;319(20):2069. doi:https://doi.org/10.1001/jama.2018.6258
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: